☆ 4.8 Review

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article Hematology

HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation

Brian M. Dulmovits et al.

Summary: High mobility group box-1 protein (HMGB1) interferes with EPO signaling pathways, leading to reduced expansion and increased death of EPO-sensitive erythroid precursors in patients with anemia of inflammation. This study provides important insights into the chronic phase of anemia of inflammation.

BLOOD (2022)

添加到收藏夹
Editorial Material Hematology

Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies

Do Hwan Kim et al.

BLOOD (2022)

添加到收藏夹
Article Oncology

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment

Matias Autio et al.

Summary: This study characterized the spatial organization and phenotype of tumor-infiltrating immune cells in DLBCL and found that the content of macrophages and T cells correlates with patient survival. The presence of high T-cell/low macrophage content in the lymphoma microenvironment is associated with superior survival, while the presence of CD163-macrophages expressing high levels of PD-L1 and TIM3 is associated with poor outcome.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹
Article Oncology

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Poornima Sharma et al.

Summary: In March 2021, the FDA approved a new treatment for adult patients with relapsed/refractory multiple myeloma. The treatment showed a high overall response rate and complete response rate, with a prolonged duration of response. However, there were also serious adverse reactions and potential risks associated with the treatment.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹
Review Immunology

Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy

Arianna Pocaterra et al.

Summary: This review highlights the benefits of combining adoptive T cell therapy (ACT) with conventional chemo and/or radiotherapy for the treatment of solid tumors. Despite the challenges such as sub optimal T cell engraftment, tumor infiltration, poor tumor antigenicity/immunogenicity, and immunosuppression, recent advances show that these concomitant treatments can help overcome these barriers and promote a more favorable microenvironment for tumor eradication.

CURRENT OPINION IN IMMUNOLOGY (2022)

添加到收藏夹
Article Oncology

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Yuanyan Tang et al.

Summary: The study showed that BCMA-CD38 bispecific CAR-T cell therapy is effective in treating R/R MM patients, with high response rate, low recurrence rate, and manageable cytokine release syndrome (CRS), providing a promising treatment option.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹
Article Biotechnology & Applied Microbiology

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Yang Wu et al.

Summary: The study demonstrated an effective CAR-T cell treatment for CD30-positive PTCL tumors by using CD30 CAR T cells to suppress tumor growth.

CANCER GENE THERAPY (2022)

添加到收藏夹
Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson et al.

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

添加到收藏夹
Article Multidisciplinary Sciences

Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells

J. Joseph Melenhorst et al.

Summary: CAR T cells redirected to target CD19 demonstrated long-lasting potential and clonal stability in two patients with chronic lymphocytic leukaemia. Highly activated CD4(+) cells emerged and dominated the CAR T cell population at later time points. These unexpected CAR T cell populations provide novel insights into anti-cancer response and long-term remission in leukaemia.

NATURE (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler et al.

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

添加到收藏夹
Article Multidisciplinary Sciences

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Derek P. Wong et al.

Summary: In this study, a BAFF ligand-based CAR-T cell therapy is developed, which can recognize and kill multiple B cell cancers by binding to three different receptors, reducing the risk of antigen escape.

NATURE COMMUNICATIONS (2022)

添加到收藏夹
Article Oncology

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

Guoxing Zhao et al.

Summary: A 51-year-old male patient with refractory multiple myeloma was successfully treated with combined anti-BCMA CAR-T and lenalidomide therapy after failing previous CAR-T treatment. The patient achieved a very good partial response 14 days post-treatment, which was sustained for over 8 months, demonstrating the feasibility and effectiveness of this combination therapy in relapsed or refractory multiple myeloma.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹
Article Immunology

Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β

Leah M. Alabanza et al.

Summary: It has been found that armored BCMA CAR T cells can effectively eliminate multiple myeloma and resist the inhibitory effects of TGF-beta. This study provides new insights for the treatment of multiple myeloma.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹
Article Oncology

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Marc Wehrli et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy, while effective in treating tumors, is associated with acute toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Current treatment guidelines for CRS and ICANS recommend the use of tocilizumab and corticosteroids. This study retrospectively analyzed the use of anakinra, a drug that blocks the interleukin-1 receptor, in managing steroid-refractory ICANS. The use of anakinra resulted in significant reduction in fever and inflammatory cytokines, but did not have a dramatic effect on neurotoxicity or the tapering of corticosteroids.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹
Article Hematology

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

Krishna R. Juluri et al.

Summary: CD19-targeted CAR T-cell therapy has shown significant efficacy in patients with B-cell malignancies, but is associated with toxicities such as CRS and neurotoxicity. Research suggests that the severity of CRS and prelymphodepletion platelet count are independent predictors of hematologic toxicity.

BLOOD ADVANCES (2022)

添加到收藏夹
Article Hematology

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

Timothy J. Voorhees et al.

Summary: This study found an association between high baseline MTV and inferior PFS in patients with r/r cHL treated with CD30.CAR-T cell therapy.

BLOOD ADVANCES (2022)

添加到收藏夹
Review Immunology

CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

Timothy N. J. Bullock

Summary: Advances in checkpoint blockade immunotherapies have led to an expansion in methods for promoting T cell access to the tumor microenvironment, with dendritic cells playing a crucial role in the immune response to tumor antigens. The role of CD40 as a master regulator of dendritic cell activation in cancer vaccines and other immune-oncology approaches is highlighted and evaluated.

CELLULAR & MOLECULAR IMMUNOLOGY (2022)

添加到收藏夹
Article Hematology

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Paul M. Maciocia et al.

Summary: CCR9 expression is found in the majority of T-ALL cases, making it a potential target for CAR-T cell therapy. CAR-T cells targeting CCR9 can effectively inhibit leukemia cell proliferation without harming healthy T cells, providing a promising treatment strategy for T-ALL.

BLOOD (2022)

添加到收藏夹
Letter Oncology

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis

Ricardo D. Parrondo et al.

BLOOD CANCER JOURNAL (2022)

添加到收藏夹
Article Oncology

Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism

Quanjun Yang et al.

Summary: Accumulated oncometabolites in the tumor microenvironment suppress T cell metabolism and function. Inhibition of glucose uptake by Kynurenine (Kyn) affects CD8 + T cell expansion and impairs CAR-T cell mediated cytotoxicity. KYNU over-expression in CAR-T cells improves anti-tumor activity in an immunosuppressive TME with high Kyn levels.

ONCOIMMUNOLOGY (2022)

添加到收藏夹
Article Hematology

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

Saar Gill et al.

Summary: Adding autologous anti-CD19 humanized binding domain T cells (huCART-19) to ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) who did not achieve complete remission (CR) despite >= 6 months of ibrutinib resulted in high rates of deep and durable remissions.

BLOOD ADVANCES (2022)

添加到收藏夹
Review Immunology

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Emma C. Morris et al.

Summary: CAR T cell therapy has revolutionized the field of cancer treatment, but significant toxicities can occur in up to one-third of patients. The most common toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Understanding their pathophysiology is crucial for developing novel therapeutics for prevention and management.

NATURE REVIEWS IMMUNOLOGY (2022)

添加到收藏夹
Article Hematology

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells

Marika Guercio et al.

Summary: A novel CAR.CD30 T cell therapy approach was designed and preclinically validated for chemotherapy-refractory or multiply relapsed CD30(+) NHL or HL. Through enhancing the co-stimulatory molecule CD28.OX40 in CAR.CD30 T cells, improved persistence and proliferation upon tumor encounter in vivo were achieved, leading to promising anti-tumor efficacy in HL and NHL xenograft mouse models.

HAEMATOLOGICA (2021)

添加到收藏夹
Review Biophysics

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges

Binod Dhakal et al.

Summary: CAR-T cell therapy has shown unprecedented efficacy in treating multiple myeloma, but still faces challenges such as relapse, drug resistance, and toxic reactions. The development of multi-targeted CAR-T antigens and combinatorial therapies is the direction to overcome these challenges.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹
Article Hematology

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

Paolo Strati et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 can lead to long-term adverse effects such as cytopenia and immune deficiency. Prolonged monitoring and prophylaxis against opportunistic infections are crucial to improve the long-term safety of this therapy.

HAEMATOLOGICA (2021)

添加到收藏夹
Review Hematology

Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies

Takayuki Ikezoe

Summary: Haematological malignancies can cause DIC, with concomitant poor prognosis. The Japanese Society on Thrombosis and Hemostasis has released new DIC diagnostic criteria and recombinant human soluble thrombomodulin is commonly used for treatment. Innovative therapies like HSCT and CAR-T-cell therapy can cure some patients with haematological malignancies, but may lead to coagulopathy.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹
Review Pharmacology & Pharmacy

Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint

TingTing Tang et al.

Summary: The CD40 receptor and its ligand CD40L play a critical role in immune activation, with various therapeutic agents targeting this interaction showing promising clinical efficacy in treating malignancies and autoimmune diseases. The signaling pathways activated by CD40/CD40L interaction lead to immune cell activation and modulation, making it an attractive target for immunotherapy. Ongoing and completed clinical trials have demonstrated the potential of CD40/CD40L-targeted therapy in activating immune responses and treating diseases.

PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹
Article Engineering, Biomedical

CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

Guozhu Xie et al.

Summary: Therapies using CAR-T cells targeting tumor-specific driver gene mutations show potent and specific cytotoxic activity against acute myeloid leukemia, potentially avoiding harmful effects on normal tissues.

NATURE BIOMEDICAL ENGINEERING (2021)

添加到收藏夹
Article Hematology

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Di Wang et al.

Summary: CT103A, a fully human BCMA-specific CAR T-cell therapy, has shown safety and high efficacy in patients with relapsed/refractory multiple myeloma, including those who had prior exposures to murine BCMA CAR therapy. Its overall response rate reaches 100%, with a significant portion achieving complete response or stringent complete response. Hematologic toxicities are common adverse events, but no immune effector cell-associated neurotoxicity syndrome was observed. Detection of CAR transgenes and median CAR transgene persistence support the potential of CT103A as a promising therapy for RRMM.

BLOOD (2021)

添加到收藏夹
Article Oncology

Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies

Zhenling Guo et al.

Summary: CD19-specific CAR T-cell therapy has shown significant efficacy in treating B-cell hematological malignancies, but targeted antigen-negative relapse poses a challenge to its widespread application. Researchers have explored alternative targets and tested combination antigen CAR T-cell therapies to enhance treatment effectiveness.

CANCER SCIENCE (2021)

添加到收藏夹
Article Oncology

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Shiqi Li et al.

Summary: The study reports two cases of patients with relapsed/refractory T-ALL treated with GC027, showing robust expansion of CAR-T cells and rapid eradication of CD7(+) T lymphoblasts. Both patients achieved complete remission with no minimal residual disease. One patient remained in ongoing remission for over 1 year after CAR T-cell infusion. Grade 3 cytokine release syndrome occurred in both patients and was managed with a novel approach using ruxolitinib. No graft-versus-host disease was observed. These findings suggest that GC027 may be a promising new approach for treating refractory/relapsed T-ALL. Further studies are needed.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹
Review Immunology

The blood-brain barrier in systemic infection and inflammation

Ian Galea

Summary: The vascular blood-brain barrier serves as a regulated interface between the blood and brain, protecting neurons and signaling inflammation and infection to the brain. As systemic inflammation exacerbates, the barrier becomes more permeable, leading to increased lymphocyte trafficking and potential endothelial cell damage. Further research is needed to understand the varied response of the blood-brain barrier to systemic inflammation.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹
Article Oncology

Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia

Guoqiang Lin et al.

Summary: The study evaluated the effectiveness of CAR-T cells targeting CLL-1 combined with PD-1 silencing therapy for AML, suggesting it as a potential immunotherapy for relapsed or refractory AML.

MOLECULAR MEDICINE REPORTS (2021)

添加到收藏夹
Article Cell Biology

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

Max Jan et al.

Summary: Cell-based therapies, particularly CAR T cells, are increasingly recognized as powerful agents against cancer. By utilizing the drug lenalidomide, researchers have successfully developed ON and OFF switches to control the function of CAR T cells, showing promising clinical applications for these engineered cells.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹
Article Cell Biology

DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities

Tian Deng et al.

Summary: CAR-T transfer, a rapidly developing immunotherapy, is showing substantial benefits for advanced cancer patients, but is also associated with potentially fatal adverse effects like cytokine release syndrome and neurotoxicity. Understanding the mechanisms behind these toxicities is crucial for improving therapeutic outcomes. Recent studies emphasize the importance of monocytes/macrophages in CAR-T-related toxicities and reveal a novel mechanism mediated by DAMPs released from pyroptotic cells.

CELL DEATH & DISEASE (2021)

添加到收藏夹
Article Oncology

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Heng Mei et al.

Summary: Bispecific BM38 CAR-T cells showed strong efficacy in patients with refractory or relapsed multiple myeloma (RRMM), with good clinical responses and manageable toxicities.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Letter Oncology

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity

Jiangzhou Shi et al.

Summary: The study demonstrates that anti-CD99 CAR T cells can specifically recognize and efficiently eliminate CD99+ leukemia cells.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy

Rujiao Dong et al.

Summary: This study evaluated the association between cytokine release syndrome (CRS) and efficacy after anti-CD19 CAR-T therapy in 22 patients with relapsed/refractory B cell hematological malignancies. The findings showed that patients with >= grade 2 CRS had higher complete remission rates (CR) and longer progression-free survival (PFS), and bridging hematopoietic stem cell transplantation was another independent predictor for PFS. The data suggested that appropriate CRS may be beneficial to the efficacy of CAR-T therapy.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2021)

添加到收藏夹
Article Hematology

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

John H. Baird et al.

Summary: CAR T-cell therapy targeting CD19 improves outcomes in LBCL treatment, but long-term monitoring of hematologic recovery, immune reconstitution, and antimicrobial prophylaxis is necessary for patients post-treatment.

BLOOD ADVANCES (2021)

添加到收藏夹
Letter Hematology

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke et al.

BLOOD (2021)

添加到收藏夹
Article Biophysics

CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial

Mi Shao et al.

Summary: CAR-T cell therapy targeting BCMA has shown promising effects in R/R MM patients, with a high response rate but also a high incidence of adverse events. All 37 patients experienced CRS, and 91% had abnormal coagulation parameters. Coagulation parameters were positively correlated with CRS severity and levels of certain cytokines.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹
Article Oncology

B-Cell Lymphomas, Version 5.2021 Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz et al.

Summary: In the past decade, advancements in understanding the molecular pathogenesis of B-cell non-Hodgkin lymphomas have led to the development of novel targeted therapies, including small molecule inhibitors of select kinases, antibody-drug conjugates, and small molecules targeting various proteins. These therapies, such as anti-CD19 CAR T-cell therapy, have been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma, and also show promise for follicular lymphoma and mantle cell lymphoma. These developments are highlighted in the NCCN Guidelines for B-Cell Lymphomas.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹
Article Oncology

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Jessica Wenthe et al.

Summary: LOAd703, an immunostimulatory oncolytic adenovirus, shows potential in enhancing anti-lymphoma immune responses and improving CAR T-cell therapy efficacy in B-cell lymphoma models. LOAd703-infected lymphoma cells can stimulate CAR T-cell functionality resulting in enhanced cytokine release, degranulation marker expression, and reduced inhibitory receptor expression, leading to increased lymphoma cell killing. Additionally, LOAd703-infected lymphoma cells upregulate secretion of chemokines essential for immune cell homing, facilitating enhanced CAR T-cell migration.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹
Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹
Article Cell Biology

An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CART cells and clearance of bulky lymphoma

Paul-Joseph Aspuria et al.

Summary: CAR-T cells show durable responses in refractory hematological tumors, but effective control of CAR-T cell population is crucial to prevent tumor progression. An orthogonal IL-2 receptor/ligand system provides specific in vivo control of CAR-T cell expansion and activation, enhancing efficacy of CAR-T therapies.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹
Article Cell Biology

A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia

Qian Zhang et al.

Summary: Researchers have successfully created a pair of human orthogonal IL-2 and orthogonal IL-2 receptor through engineering, which can deliver IL-2 signal without toxicity, and demonstrated that this approach can enhance the antitumor efficacy of engineered T cells.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹
Article Multidisciplinary Sciences

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Mehmet Kemal Samur et al.

Summary: Relapse following BCMA targeted CAR T-cell therapy in multiple myeloma patients is often due to biallelic loss of BCMA, which hinders the proliferation of CAR T cells and results in lack of response to retreatment. Single cell genomic characterization is essential for detecting BCMA gene alterations to improve treatment outcomes.

NATURE COMMUNICATIONS (2021)

添加到收藏夹
Article Multidisciplinary Sciences

Direct control of CAR T cells through small molecule-regulated antibodies

Spencer Park et al.

Summary: Many next-generation antibody therapeutics have enhanced potency but also come with the risk of adverse events. The authors of this study have developed a conditionally activated, single-module CAR.

NATURE COMMUNICATIONS (2021)

添加到收藏夹
Article Multidisciplinary Sciences

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

Nadia El Khawanky et al.

Summary: The success of CAR-T cells in treating AML is constrained by their toxicity to normal cells and low persistence. This study demonstrates that the demethylating compound 5'-Azacitdine can enhance anti-CD123 CAR-T cell cytotoxicity against AML cells. Additionally, the development of third-generation anti-CD123 CAR-T cells shows promising results in targeting AML cells without affecting healthy hematopoietic system.

NATURE COMMUNICATIONS (2021)

添加到收藏夹
Article Immunology

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Deming Duan et al.

Summary: BCMA-7 x 19 CAR-T cells have shown superior efficacy and safety in treating refractory/relapsed multiple myeloma, making them a promising therapeutic option that warrants further clinical studies.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Letter Oncology

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy

Di Wang et al.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹
Article Oncology

A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

Chunrui Li et al.

Summary: The study evaluated the safety and efficacy of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and primary plasma cell leukemia patients, revealing that this treatment is safe and highly active, with potential therapeutic value.

CLINICAL AND TRANSLATIONAL MEDICINE (2021)

添加到收藏夹
Article Hematology

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer et al.

Summary: CD70 is a promising target antigen for AML treatment, and CD70-CAR T cells demonstrate good proliferation and antitumor activity in vitro and in vivo for CD70-positive AML patients, showing potential as a new treatment strategy.

BLOOD (2021)

添加到收藏夹
Article Oncology

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma

Meijing Liu et al.

Summary: For patients with refractory B-cell lymphoma, the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy combined with ibrutinib salvage treatment showed promising therapeutic effects in some patients, leading to complete response or partial remission. However, this treatment approach also resulted in higher levels of cytokine release syndrome and more severe hematological toxicity compared to the first-time therapy.

CANCER SCIENCE (2021)

添加到收藏夹
Article Oncology

Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis

Lisa C. Holthof et al.

Summary: The microenvironment of multiple myeloma can impact therapy outcome, with bone marrow mesenchymal stromal cells protecting MM cells from lysis by certain CAR T cells. BMMSCs did not protect against high-affinity, strongly lytic CAR T cells, but significantly protected against lower affinity, moderately lytic CAR T cells in a cell-cell contact-dependent manner. The study suggests that inhibition of antiapoptotic proteins upregulated in MM cells through BMMSC interactions may improve the outcome of CAR T cell or conventional CTL therapies.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹
Article Immunology

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

Yimei Que et al.

Summary: Based on the analysis of clinical trial results of anti-BCMA CAR-T cell therapy, it was found that patients with extramedullary multiple myeloma could benefit from this treatment in terms of safety, efficacy, and pharmacokinetics, although they had shorter overall survival and progression-free survival compared to non-extramedullary multiple myeloma patients.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Article Biochemistry & Molecular Biology

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

Sabrina Prommersberger et al.

Summary: Clinical development of CAR-T-cell therapy has been advanced by synthetic biology, genetic engineering, and clinical-grade manufacturing, with the goal of providing safe, effective, and economically sustainable treatment. The CARAMBA project aims to demonstrate virus-free CAR gene transfer using advanced SB transposon technology, potentially improving vector procurement, CAR-T manufacturing, and distribution. The project focuses on utilizing SB-based CAR-T cells targeting the SLAMF7 antigen in multiple myeloma, with promising preclinical results indicating potent anti-myeloma activity.

GENE THERAPY (2021)

添加到收藏夹
Article Oncology

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

Emiliano Roselli et al.

Summary: The study demonstrates that combining 4-1BB with an optimized form of CD28 for co-stimulation is an effective way to enhance CAR T cell function. Both mono-specific and bi-specific versions of this design show improved expansion, persistence, and resistance to exhaustion in vitro and in vivo.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹
Article Oncology

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy

Limin Xing et al.

Summary: CAR-T cells have shown good efficacy in treating certain refractory B-cell tumors, but their main toxicities include cytokine release syndrome, neurotoxicity syndrome, cytopenia, and severe infection. The use of sirolimus may help inhibit CAR-T cell toxicity, restore normal hematopoiesis, improve efficacy, and does not affect remission status.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹
Review Cell Biology

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia

Debora Bifano Pimenta et al.

Summary: Bone marrow is a complex tissue that regulates hematopoiesis, with AML developing in this microenvironment. Cells and molecules within the hematopoietic niche interact to influence leukemia development, suggesting that targeting the bone marrow microenvironment could be a promising strategy for AML treatment.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹
Letter Oncology

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

Francesco Paolo Tambaro et al.

LEUKEMIA (2021)

添加到收藏夹
Article Cell Biology

Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

Dina Schneider et al.

Summary: Researchers have developed a trispecific duoCAR-T cell strategy to effectively target B cell malignancies with different antigens, showing superior efficacy compared to traditional monoCAR-T cells. The combination of intracellular signaling motifs plays a crucial role in the antitumor effects of duoCAR-T cells.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹
Letter Oncology

A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL

Yue Tan et al.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹
Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

添加到收藏夹
Article Hematology

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia

Hardikkumar Jetani et al.

Summary: Siglec-6 can serve as a novel target for CAR T cell therapy in AML, effectively eliminating AML cells without affecting normal hematopoietic stem cells. This therapy may also be applicable to CLL, with limited on-target/off-tumor reactivity on normal mature hematopoietic cells.

BLOOD (2021)

添加到收藏夹
Article Immunology

Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia

Lichun Xie et al.

Summary: This study investigated the use of autologous CD7-CAR T cells (4SCAR7) for the treatment of T-ALL in an 11-year-old patient and found it to be safe and effective. The patient experienced cytopenia for a period of time during remission induction after CAR-T cell therapy, but eventually achieved remission.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹
Article Oncology

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Regina M. Myers et al.

Summary: In this study, huCART19 demonstrated high overall response rates in children and young adults with relapsed or refractory B-ALL, reaching 98% in the CAR-naive cohort and 100% in B-ALL patients. Despite common adverse events such as neurologic toxicities and cytokine release syndrome, these were mostly fully resolved, indicating durable remissions with long-term persistence achieved by huCART19.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹
Article Oncology

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Jing Pan et al.

Summary: Donor-derived anti-CD7 CAR T cells showed efficient expansion and high complete remission rate in patients with r/r T-ALL, with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹
Letter Oncology

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Qingya Cui et al.

Summary: The study demonstrated the potential efficacy and safety of CD38-targeted CAR-T cells in treating relapsed AML patients by eliminating CD38 positive blasts without off-target effects, although the risk of relapse still exists.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

添加到收藏夹
Article Biotechnology & Applied Microbiology

A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL

Samanta Romina Zanetti et al.

MOLECULAR THERAPY (2021)

添加到收藏夹
Article Oncology

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies

Sanmei Wang et al.

Summary: CAR T cells targeting CD19 have shown impressive clinical responses in lymphoid malignancies, but resistance and relapse remain challenges. Combining CAR T cells with selective inhibitors of nuclear export (SINEs) targeting XPO1 may reduce the risk of tumor escape, although simultaneous use of SINEs and CAR T cells may impair CAR T cell function. Sequential use of SINEs and CAR T cells could potentially enhance the anti-tumor efficacy of CAR T cells.

ONCOLOGY REPORTS (2021)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

Haibo Zhu et al.

Summary: The anti-CD22-CAR T cell salvage therapy showed higher efficacy in R/R DLBCL patients compared to R/R B-ALL patients who had failed anti-CD19-CAR T cell therapy before. Further studies with larger sample sizes are needed for confirmation.

ONCOTARGETS AND THERAPY (2021)

添加到收藏夹
Article Oncology

CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study

Guoqing Wei et al.

Summary: Dual-targeted CAR T cells against CD19 and CD22 show promising antilymphoma effects in patients with relapsed/refractory aggressive B-cell lymphoma, with high objective response and complete response rates. The study suggests that achieving complete response and receiving fewer lines of prior chemotherapy are independent prognostic factors associated with favorable progression-free survival.

CANCER IMMUNOLOGY RESEARCH (2021)

添加到收藏夹
Article Immunology

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

Ping Li et al.

Summary: CAR-T cell therapy is a novel treatment for hematologic malignancies, but poses a risk of HBV reactivation in patients with resolved infections. Close monitoring of HBV DNA levels is necessary, particularly in HBsAb-negative individuals who may benefit from antiviral prophylaxis.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Article Immunology

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

Haobin Deng et al.

Summary: This study observed the efficacy and safety of humanized anti-BCMA chimeric antigen receptor (CAR) T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. It was found that patients with extramedullary disease benefited in the short term from the therapy, although they experienced higher grades of cytokine release syndrome and immune effector cell-associated neurotoxic syndrome.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹
Article Hematology

CAR T-cell therapy for multiple myeloma: state of the art and prospects

Niels W C J van de Donk et al.

Lancet Haematology (2021)

添加到收藏夹
Article Oncology

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

Rebecca Baur et al.

Summary: CAR-T cell therapy shows promise in treating relapsed or refractory lymphoma and leukemia, but can lead to hematotoxicity, including anemia and thrombocytopenia, which may increase the risk of infection or bleeding. Additional supportive measures such as Romiplostim may be used to manage these toxicities, but further clinical studies are needed to confirm the efficacy of this approach.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹
Article Oncology

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation

Anthony M. Battram et al.

Summary: This study found that CAR-T cells expanded with IL-15 had reduced dysfunction and enhanced persistence compared to those grown with IL-2 or a combination of IL-15 and IL-7, resulting in longer and improved anti-tumor responses in a mouse model. Therefore, the use of IL-15 instead of IL-2 or IL-15/IL-7 should be considered in designing CAR-T cell production protocols to improve patient response duration.

CANCERS (2021)

添加到收藏夹
Article Hematology

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Andrew Johnsrud et al.

Summary: Bleeding and thrombotic events are emerging toxicities associated with CAR therapies, with incidences of 9.4% and 6.3% respectively in this study. The severity of ICANS is significantly associated with the occurrence of bleeding and thrombosis, and low platelet count is a risk factor for bleeding.

BLOOD ADVANCES (2021)

添加到收藏夹
Article Oncology

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

Jan-Erik Meyer et al.

Summary: Targeting CD123 with CAR-T therapy shows promise in treating AML, but the risk of toxicity from non-specific cell targeting remains a concern. A new UniCAR platform with a switchable adapter system, including a CD123-specific TM variant for transient costimulation, has shown improved safety and efficacy in preclinical models. This approach may provide a flexible and individualized treatment option for AML patients.

ONCOIMMUNOLOGY (2021)

添加到收藏夹
Review Hematology

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma

Albert Oriol et al.

Summary: The development of multiple treatment options has improved patient survival in multiple myeloma, but drug resistance remains a challenge for high-risk patients, necessitating the development of new agents with different mechanisms of action.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

添加到收藏夹
Article Immunology

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression

Evripidis Lanitis et al.

Summary: Limited clinical benefit has been shown for CAR therapy in solid tumors, but fourth-generation CAR-T cells coengineered with mIL-15 are being developed to enhance responses. Technical challenges have limited preclinical studies using immunocompetent mice, but optimized methods for efficient transduction and expansion of T lymphocytes in murine models have been described. The bicistronic retroviral vector encoding a tumor vasculature-targeted CAR and mIL-15 shows enhanced effector functions and potential for TME reprogramming, with upregulation of antiapoptotic markers and downregulation of inhibitory receptors.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹
Review Hematology

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies

Larysa Sanchez et al.

Summary: This review summarizes the latest efficacy and safety data from clinical studies of BCMA-targeted therapies, with a focus on ADCs and BITEs for patients with relapsed/refractory multiple myeloma. The differences among BCMA-targeted treatment modalities and their clinical implications are discussed.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

添加到收藏夹
Article Cell & Tissue Engineering

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

Jia Feng et al.

Summary: In this study, the modification of CD5 CAR to secrete an IL-15/IL-15sushi complex successfully targeted CNS-invading T-LBL, leading to the rapid ablation of lymphoblasts and remission of lymphoma in the patient. Despite the presence of CD5 on normal T cells, the treatment only caused brief, transient T-cell aplasia. These results suggest that CD5-IL15/IL15sushi CAR T cells may offer a safe and effective treatment option for T-cell malignancies, particularly for those with CNS involvement.

STEM CELL REVIEWS AND REPORTS (2021)

添加到收藏夹
Review Oncology

The nuclear export protein XPO1-from biology to targeted therapy

Asfar S. Azmi et al.

Summary: XPO1 plays a crucial role in cellular homeostasis and cancer development, with its inhibitor selinexor clinically validated and approved for multiple myeloma and diffuse large B cell lymphoma treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹
Article Hematology

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

Ying Wang et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

添加到收藏夹
Review Hematology

The immune landscape and response to immune checkpoint blockade therapy in lymphoma

Justin Kline et al.

BLOOD (2020)

添加到收藏夹
Article Hematology

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier et al.

BLOOD (2020)

添加到收藏夹
Letter Hematology

Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy

Ajai Chari et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹
Review Oncology

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

Nina Shah et al.

LEUKEMIA (2020)

添加到收藏夹
Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Multidisciplinary Sciences

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

Sabarinath V. Radhakrishnan et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹
Letter Oncology

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients

D. Wang et al.

BLOOD CANCER JOURNAL (2020)

添加到收藏夹
Letter Oncology

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia

Shuangyou Liu et al.

BLOOD CANCER JOURNAL (2020)

添加到收藏夹
Review Oncology

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy

Rebecca Epperly et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹
Article Immunology

Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome

Yuying Liu et al.

SCIENCE IMMUNOLOGY (2020)

添加到收藏夹
Article Hematology

Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Maria-Luisa Schubert et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Jessica Wenthe et al.

CANCER GENE THERAPY (2020)

添加到收藏夹
Review Immunology

Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies

Wenting Song et al.

CLINICAL IMMUNOLOGY (2020)

添加到收藏夹
Article Oncology

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma

Christopher M. Wright et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

添加到收藏夹
Article Oncology

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹
Article Biotechnology & Applied Microbiology

In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes

Shiwani Agarwal et al.

MOLECULAR THERAPY (2020)

添加到收藏夹
Article Oncology

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Simon Loff et al.

MOLECULAR THERAPY-ONCOLYTICS (2020)

添加到收藏夹
Review Oncology

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance

Lisa C. Holthof et al.

CANCERS (2020)

添加到收藏夹
Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹
Article Hematology

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma

Chuan Tong et al.

BLOOD (2020)

添加到收藏夹
Review Hematology

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Joshua A. Hill et al.

BLOOD (2020)

添加到收藏夹
Article Oncology

Phase II trial of co-administration of CD19-and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Wei Sang et al.

CANCER MEDICINE (2020)

添加到收藏夹
Article Immunology

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

Meir Rozenbaum et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹
Article Oncology

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

Matteo Libero Baroni et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹
Article Oncology

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

Jia Wei et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹
Article Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Carlos A. Ramos et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹
Article Hematology

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

Chelsea C. Pinnix et al.

BLOOD ADVANCES (2020)

添加到收藏夹
Editorial Material Hematology

Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma

Paolo Strati et al.

BLOOD ADVANCES (2020)

添加到收藏夹
Article Hematology

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain et al.

BLOOD ADVANCES (2020)

添加到收藏夹
Review Oncology

Macrophage, the potential key mediator in CAR-T related CRS

Zhaonian Hao et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹
Article Hematology

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

Eugenio D. Hottz et al.

BLOOD (2020)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

Cesar Sommer et al.

MOLECULAR THERAPY (2020)

添加到收藏夹
Article Oncology

Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro

Meijing Liu et al.

CANCER SCIENCE (2020)

添加到收藏夹
Article Biochemistry & Molecular Biology

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Carsten Riether et al.

NATURE MEDICINE (2020)

添加到收藏夹
Article Cell & Tissue Engineering

Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells

Martin Stach et al.

CYTOTHERAPY (2020)

添加到收藏夹
Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

添加到收藏夹
Article Biochemistry & Molecular Biology

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng et al.

NATURE MEDICINE (2020)

添加到收藏夹
Article Biochemistry & Molecular Biology

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah et al.

NATURE MEDICINE (2020)

添加到收藏夹
Article Immunology

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

Liangshun You et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹
Article Oncology

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus

Lu Han et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹
Review Immunology

Cytokines in CAR T Cell-Associated Neurotoxicity

Juliane Gust et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹
Meeting Abstract Hematology

Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (BALL)

Junfang Yang et al.

BLOOD (2020)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy

Chunmei Yang et al.

ONCOTARGETS AND THERAPY (2020)

添加到收藏夹
Article Biochemistry & Molecular Biology

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma

Jianshu Wei et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹
Review Rheumatology

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Puja Mehta et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹
Article Cell & Tissue Engineering

Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies

Masayuki Wada et al.

STEM CELL REVIEWS AND REPORTS (2020)

添加到收藏夹
Review Immunology

DAMP-sensing receptors in sterile inflammation and inflammatory diseases

Tao Gong et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹
Review Immunology

The gasdermins, a protein family executing cell death and inflammation

Petr Broz et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹
Article

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Sattva S. Neelapu et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹
Article Biophysics

Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹
Article Oncology

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

Nicholas F. Kuhn et al.

CANCER CELL (2019)

添加到收藏夹
Review Biochemistry & Molecular Biology

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma

Moo-Kon Song et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹
Article Biochemistry & Molecular Biology

Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators

Mohit Sachdeva et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

添加到收藏夹
Article Multidisciplinary Sciences

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Mohamad Hamieh et al.

NATURE (2019)

添加到收藏夹
Article Cell Biology

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹
Article

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

Chuang Sun et al.

Oncotarget (2019)

添加到收藏夹
Article Oncology

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

Darya Alizadeh et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹
Article Hematology

Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy

Huiwen Jiang et al.

ANNALS OF HEMATOLOGY (2019)

添加到收藏夹
Review Cell Biology

Chimeric antigen receptor T cell persistence and memory cell formation

Alexander D. McLellan et al.

IMMUNOLOGY AND CELL BIOLOGY (2019)

添加到收藏夹
Article Oncology

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

Jing Pan et al.

LEUKEMIA (2019)

添加到收藏夹
Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹
Article Oncology

Effect and changes in PD-1 expression of CD19 CAR-T cells from T cells highly expressing PD-1 combined with reduced-dose PD-1 inhibitor

Rui Zhang et al.

ONCOLOGY REPORTS (2019)

添加到收藏夹
Article Multidisciplinary Sciences

leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Jie Xu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹
Article Oncology

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Eric L. Smith et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹
Article Oncology

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

Austin J. Sim et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma

Sujun Li et al.

ONCOTARGETS AND THERAPY (2019)

添加到收藏夹
Letter Cell Biology

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects

Jianxia Zhou et al.

PROTEIN & CELL (2019)

添加到收藏夹
Article Hematology

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Margot J. Pont et al.

BLOOD (2019)

添加到收藏夹
Article Pharmacology & Pharmacy

Selinexor: First Global Approval

Yahiya Y. Syed

DRUGS (2019)

添加到收藏夹
Article Oncology

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

Melissa Works et al.

MOLECULAR CANCER THERAPEUTICS (2019)

添加到收藏夹
Review Medicine, General & Internal

Anemia of Inflammation

Tomas Ganz

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹
Article Oncology

CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report

Jia Wang et al.

ONCOLOGY LETTERS (2019)

添加到收藏夹
Article Oncology

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Yaqing Cao et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹
Article Oncology

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy

Hui Luo et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹
Article Hematology

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Rosalie M. Sterner et al.

BLOOD (2019)

添加到收藏夹
Article Biophysics

A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia

Yongxian Hu et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹
Article Medicine, General & Internal

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven Horwitz et al.

LANCET (2019)

添加到收藏夹
Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

添加到收藏夹
Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹
Article Hematology

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

Andrea Schmidts et al.

BLOOD ADVANCES (2019)

添加到收藏夹
Review Immunology

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations

Robert Weinkove et al.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)

添加到收藏夹
Article Biochemistry & Molecular Biology

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry et al.

NATURE MEDICINE (2018)

添加到收藏夹
Review Cell & Tissue Engineering

Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies

Michael D. Jain et al.

STEM CELLS (2018)

添加到收藏夹
Article Hematology

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Michelle A. Fanale et al.

BLOOD (2018)

添加到收藏夹
Review Hematology

The potential role of gamma delta T cells after allogeneic HCT for leukemia

Rupert Handgretinger et al.

BLOOD (2018)

添加到收藏夹
Article Immunology

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

Jae H. Park et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹
Review Immunology

CD4 Helper and CD8 Cytotoxic T Cell Differentiation

Ichiro Taniuchi

ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)

添加到收藏夹
Article Oncology

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia

Jinghua Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

添加到收藏夹
Article Oncology

CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib

Hardikkumar Jetani et al.

LEUKEMIA (2018)

添加到收藏夹
Article Biochemistry & Molecular Biology

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Margherita Norelli et al.

NATURE MEDICINE (2018)

添加到收藏夹
Article Biochemistry & Molecular Biology

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Theodoros Giavridis et al.

NATURE MEDICINE (2018)

添加到收藏夹
Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹
Article Oncology

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Bianca D. Santomasso et al.

CANCER DISCOVERY (2018)

添加到收藏夹
Article Oncology

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates

Agne Taraseviciute et al.

CANCER DISCOVERY (2018)

添加到收藏夹
Article

IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner

Romy Loschinski et al.

Oncotarget (2018)

添加到收藏夹
Article Cell Biology

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Mauro P. Avanzi et al.

CELL REPORTS (2018)

添加到收藏夹
Review Immunology

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias

Vito Pistoia et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹
Article Medicine, Research & Experimental

In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome

Anett Pfeiffer et al.

EMBO MOLECULAR MEDICINE (2018)

添加到收藏夹
Article Biotechnology & Applied Microbiology

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML

Samuel John et al.

MOLECULAR THERAPY (2018)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape

Carl DeSelm et al.

MOLECULAR THERAPY (2018)

添加到收藏夹
Article Biotechnology & Applied Microbiology

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

Carlos A. Ramos et al.

MOLECULAR THERAPY (2018)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Sarwish Rafiq et al.

NATURE BIOTECHNOLOGY (2018)

添加到收藏夹
Article Biochemistry & Molecular Biology

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Marco Ruella et al.

NATURE MEDICINE (2018)

添加到收藏夹
Article Biochemistry & Molecular Biology

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Elena J. Orlando et al.

NATURE MEDICINE (2018)

添加到收藏夹
Article Clinical Neurology

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

Juliane Gust et al.

CNS DRUGS (2018)

添加到收藏夹
Review Oncology

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells

Marion Alcantara et al.

LEUKEMIA (2018)

添加到收藏夹
Article Medicine, Research & Experimental

4-1BB enhancement of CAR T function requires NF-κB and TRAFs

Gongbo Li et al.

JCI INSIGHT (2018)

添加到收藏夹
Article Hematology

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma

Lydia Lee et al.

BLOOD (2018)

添加到收藏夹
Article Hematology

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

Joshua A. Hill et al.

BLOOD (2018)

添加到收藏夹
Article Oncology

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chun-Meng Wang et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹
Article Medicine, Research & Experimental

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

Carlos A. Ramos et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

添加到收藏夹
Review Cell Biology

Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche

Fotis Asimakopoulos et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2017)

添加到收藏夹
Article Oncology

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients

J. Pan et al.

LEUKEMIA (2017)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

Iulia Diaconu et al.

MOLECULAR THERAPY (2017)

添加到收藏夹
Article Biochemistry & Molecular Biology

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Paul M. Maciocia et al.

NATURE MEDICINE (2017)

添加到收藏夹
Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹
Article Oncology

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Marco Ruella et al.

CANCER DISCOVERY (2017)

添加到收藏夹
Editorial Material Oncology

CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity

Crystal L. Mackall et al.

CANCER DISCOVERY (2017)

添加到收藏夹
Article Oncology

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells

Thomas Shum et al.

CANCER DISCOVERY (2017)

添加到收藏夹
Article Oncology

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Juliane Gust et al.

CANCER DISCOVERY (2017)

添加到收藏夹
Article Hematology

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes

Tea Gogishvili et al.

BLOOD (2017)

添加到收藏夹
Letter Biochemistry & Molecular Biology

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials

Wen-ying Zhang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)

添加到收藏夹
Letter Hematology

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights

Amrom E. Obstfeld et al.

BLOOD (2017)

添加到收藏夹
Article Oncology

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus

Emma Eriksson et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹
Review Medicine, Research & Experimental

Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts

Jessica Hartmann et al.

EMBO MOLECULAR MEDICINE (2017)

添加到收藏夹
Article Cell & Tissue Engineering

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function

Nathan Singh et al.

CYTOTHERAPY (2017)

添加到收藏夹
Article Oncology

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

K. Pinz et al.

LEUKEMIA (2016)

添加到收藏夹
Meeting Abstract Hematology

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S. Kenderian et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)

添加到收藏夹
Article Oncology

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

Vishwajith Sridharan et al.

BRITISH JOURNAL OF CANCER (2016)

添加到收藏夹
Article Hematology

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Esther Drent et al.

HAEMATOLOGICA (2016)

添加到收藏夹
Review Immunology

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

Niels W. C. J. van de Donk et al.

IMMUNOLOGICAL REVIEWS (2016)

添加到收藏夹
Article Medicine, Research & Experimental

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

Paulina J. Paszkiewicz et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹
Article Medicine, Research & Experimental

CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

Cameron J. Turtle et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹
Letter Oncology

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

Yongxian Hu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)

添加到收藏夹
Article Multidisciplinary Sciences

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

Elad Jacoby et al.

NATURE COMMUNICATIONS (2016)

添加到收藏夹
Article Hematology

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Esther Drent et al.

HAEMATOLOGICA (2016)

添加到收藏夹
Review Immunology

The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications

Michael Spiotto et al.

SCIENCE IMMUNOLOGY (2016)

添加到收藏夹
Article Hematology

γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes

Irma Airoldi et al.

BLOOD (2015)

添加到收藏夹
Article Oncology

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zeguo Zhao et al.

CANCER CELL (2015)

添加到收藏夹
Review Cell Biology

Pivotal Roles of GM-CSF in Autoimmunity and Inflammation

Aoi Shiomi et al.

MEDIATORS OF INFLAMMATION (2015)

添加到收藏夹
Article Biotechnology & Applied Microbiology

Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression

Kevin J. Curran et al.

MOLECULAR THERAPY (2015)

添加到收藏夹
Article Biochemistry & Molecular Biology

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Adrienne H. Long et al.

NATURE MEDICINE (2015)

添加到收藏夹
Article Multidisciplinary Sciences

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

Chia-Yung Wu et al.

SCIENCE (2015)

添加到收藏夹
Article Oncology

Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells

Ivan Liadi et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹
Article Oncology

Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function

Chunjian Qi et al.

CANCER INVESTIGATION (2015)

添加到收藏夹
Article Immunology

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Yao Wang et al.

CLINICAL IMMUNOLOGY (2014)

添加到收藏夹
Review Oncology

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar et al.

LANCET ONCOLOGY (2014)

添加到收藏夹
Article Hematology

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso et al.

BLOOD (2013)

添加到收藏夹
Article Hematology

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors

Nicoletta Cieri et al.

BLOOD (2013)

添加到收藏夹
Review Immunology

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

Joel Crespo et al.

CURRENT OPINION IN IMMUNOLOGY (2013)

添加到收藏夹
Editorial Material Oncology

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

Samuel T. Workenhe et al.

ONCOIMMUNOLOGY (2013)

添加到收藏夹
Editorial Material Oncology

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy

Liza B. John et al.

ONCOIMMUNOLOGY (2013)

添加到收藏夹
Article Oncology

Tumor cell recognition by γδ T lymphocytes T-cell receptor vs. NK-cell receptors

Daniel V. Correia et al.

ONCOIMMUNOLOGY (2013)

添加到收藏夹
Article Hematology

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

Djordje Atanackovic et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)

添加到收藏夹
Article Immunology

An Interleukin-21-Interleukin-10-STAT3 Pathway Is Critical for Functional Maturation of Memory CD8+ T Cells

Weiguo Cui et al.

IMMUNITY (2011)

添加到收藏夹
Article Cell Biology

The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis

Irene Mavroudi et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2011)

添加到收藏夹
Article Cardiac & Cardiovascular Systems

Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-α and IL-1β

Mohammad M. Khan et al.

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)

添加到收藏夹
Article Hematology

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity

Telma Lanca et al.

BLOOD (2010)

添加到收藏夹
Article Neurosciences

Blockade of IL-15 Activity Inhibits Microglial Activation Through the NFκB, p38, and ERK1/2 Pathways, Reducing Cytokine and Chemokine Release

Diego Gomez-Nicola et al.

GLIA (2010)

添加到收藏夹
Article Oncology

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

V. Hoyos et al.

LEUKEMIA (2010)

添加到收藏夹
Review Immunology

Molecular mechanism and function of CD40/CD40L engagement in the immune system

Raul Elgueta et al.

IMMUNOLOGICAL REVIEWS (2009)

添加到收藏夹
Article Oncology

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

Eric D. Hsi et al.

CLINICAL CANCER RESEARCH (2008)

添加到收藏夹
Article Immunology

Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival

Yoshikane Kikushige et al.

JOURNAL OF IMMUNOLOGY (2008)

添加到收藏夹
Letter Hematology

Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells

W. J. Cao et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)

添加到收藏夹
Article Immunology

GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis

Eugene D. Ponomarev et al.

JOURNAL OF IMMUNOLOGY (2007)

添加到收藏夹
Article Hematology

Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs

Dzung H. Nguyen et al.

EXPERIMENTAL HEMATOLOGY (2006)

添加到收藏夹
Article Immunology

A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry

SH Olejniczak et al.

IMMUNOLOGICAL INVESTIGATIONS (2006)

添加到收藏夹
Article Immunology

Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: A novel pathway for immune response amplification

S Danese et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹
Article Hematology

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

A Bernardo et al.

BLOOD (2004)

添加到收藏夹
Article Oncology

C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia

ABH Bakker et al.

CANCER RESEARCH (2004)

添加到收藏夹
Article Multidisciplinary Sciences

CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity

GJD van Mierlo et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

添加到收藏夹
Article Hematology

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines

G Teoh et al.

BLOOD (2000)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.